Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 58

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 58
---
 Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):September 30,2025December 31,2024Prepaid insurance$732 $421 Prepaid research and development costs203 239 Prepaid other184 113 Total$1,119 $773 

Note 6.    Accrued Expenses

Accrued expenses consisted of the following (in thousands):September 30,2025December 31,2024Accrued research and development costs$481 $374 Accrued employee compensation-related expenses15 56 Accrued other65 78 Total$561 $508 

Note 7.    Stockholders’ Equity 

At The Market Offering AgreementOn July 3, 2024, the Company entered into an At The Market Offering Agreement (the “ATM Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may sell and issue, from time to time, up to $15.0 million of shares of its common stock (the “Shares”) through Wainwright as the Company’s sales agent (the “ATM Offering”). The Company has no obligation to sell any of the Shares and may at any time suspend offers under the ATM Sales Agreement or terminate the ATM Sales Agreement pursuant to its terms. On June 18, 2025, the Company filed a prospectus supplement to adjust the maximum the Company may sell and issue under the ATM Sales Agreement to $9.65 million of its Shares (“ATM Adjustment”), not including the Shares previously sold under the ATM Sales Agreement. Since inception through September 30, 2025, the Company has issued 23,096,014 shares of common stock under the ATM Sales Agreement for net proceeds of $7.7 million. For the three months ended September 30, 2025, the Company issued 22,902,198 shares of common stock under the ATM Sales Agreement for net proceeds of $7.2 million. For the nine months ended September 30, 2025, the Company issued 23,044,194 shares of common stock under the ATM Sales Agreement for net proceeds of $7.6 million.November 2024 Registered Direct OfferingOn November 21, 2024, the Company entered into a Securities Purchase Agreement with a single healthcare focused institutional investor (the “Investor”), pursuant to which the Company